

Now Available: [Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting](#)

[Find Studies](#) | [About Clinical Studies](#) | [Submit Studies](#) | [Resources](#) | [About This Site](#)

Home > Find Studies > Study Record Detail

Text Size ▼

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

This study has been completed.

Sponsor:
Eisai Inc.

Information provided by (Responsible Party):
Eisai Inc.

ClinicalTrials.gov Identifier:
NCT00658775

First received: April 9, 2008
Last updated: November 19, 2015
Last verified: November 2015
[History of Changes](#)

[Full Text View](#)

[Tabular View](#)

[Study Results](#)

[Disclaimer](#)

[? How to Read a Study Record](#)

Results First Received: June 8, 2015

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Treatment
Condition:	Gastroesophageal Reflux Disease (GERD)
Interventions:	Drug: Rabeprazole sodium Drug: Esomeprazole

▶ Participant Flow

[Hide Participant Flow](#)

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Out of 1069 participants who were randomized, 1065 participants received study treatment.

Reporting Groups

	Description
ESO 40mg	Esomeprazole (ESO) 40mg capsule concurrently with placebo (identical in appearance to the RAB Extended Release (ER) 50mg capsule), once daily for 4 to 8 weeks.

RAB ER 50mg

Rabeprazole (RAB) Extended Release (ER) 50mg capsule concurrently with placebo (identical in appearance to the ESO 40mg capsule), once daily for 4 to 8 weeks.

Participant Flow: Overall Study

	ESO 40mg	RAB ER 50mg
STARTED	537 ^[1]	528 ^[1]
COMPLETED	495	485
NOT COMPLETED	42	43
Adverse Event	4	6
Lost to Follow-up	17	18
Withdrawal by Subject	6	4
Withdrawal of consent	8	7
Not specified	7	8

^[1] Treated

▶ Baseline Characteristics

 Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

No text entered.

Reporting Groups

	Description
ESO 40mg	Esomeprazole (ESO) 40mg capsule concurrently with placebo (identical in appearance to the RAB Extended Release (ER) 50mg capsule), once daily for 4 to 8 weeks.
RAB ER 50mg	Rabeprazole (RAB) Extended Release (ER) 50mg capsule concurrently with placebo (identical in appearance to the ESO 40mg capsule), once daily for 4 to 8 weeks.
Total	Total of all reporting groups

Baseline Measures

	ESO 40mg	RAB ER 50mg	Total
Overall Participants Analyzed [Units: Participants]	537	528	1065
Age [Units: Years] Mean (Standard Deviation)	49.1 (13.38)	51 (12.79)	50 (13.12)
Gender [Units: Participants]			
Female	195	179	374
Male	342	349	691

▶ Outcome Measures

1. Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks [Time Frame: Baseline and Week 8]

Measure Type	Primary
Measure Title	Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks
Measure Description	<p>Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:</p> <p>Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present)</p> <p>Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.</p> <p>Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.</p> <p>Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.</p>
Time Frame	Baseline and Week 8
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

ITT Population - all randomized subjects who received at least 1 dose of study drug.

Reporting Groups

	Description
ESO 40mg	Esomeprazole (ESO) 40mg capsule concurrently with placebo (identical in appearance to the RAB Extended Release (ER) 50mg capsule), once daily for 4 to 8 weeks.
RAB ER 50mg	Rabeprazole (RAB) Extended Release (ER) 50mg capsule concurrently with placebo (identical in appearance to the ESO 40mg capsule), once daily for 4 to 8 weeks.

Measured Values

	ESO 40mg	RAB ER 50mg
Participants Analyzed [Units: Participants]	537	528
Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks [Units: Percentage of Participants]		
Yes	78.4	77.5
No	16.6	18.4
Missing	5	4.2

No statistical analysis provided for Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

2. Primary: Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks [Time Frame: Baseline and

Measure Type	Primary
Measure Title	Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
Measure Description	<p>Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:</p> <p>Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present)</p> <p>Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.</p> <p>Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.</p> <p>Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.</p>
Time Frame	Baseline and Week 4
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

ITT Population

Reporting Groups

	Description
ESO 40mg	Esomeprazole (ESO) 40mg capsule concurrently with placebo (identical in appearance to the RAB Extended Release (ER) 50mg capsule), once daily for 4 to 8 weeks.
RAB ER 50mg	Rabeprazole (RAB) Extended Release (ER) 50mg capsule concurrently with placebo (identical in appearance to the ESO 40mg capsule), once daily for 4 to 8 weeks.

Measured Values

	ESO 40mg	RAB ER 50mg
Participants Analyzed [Units: Participants]	537	528
Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks [Units: Percentage of Participants]		
Yes	50.7	50.9
No	46.4	47
Missing	3	2.1

No statistical analysis provided for Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

3. Secondary: Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4 [Time Frame: Week 4]

Measure Type	Secondary
Measure Title	Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4
Measure Description	During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at

	least 7 consecutive heartburn-free days.
Time Frame	Week 4
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

ITT Population

Reporting Groups

	Description
ESO 40mg	Esomeprazole (ESO) 40mg capsule concurrently with placebo (identical in appearance to the RAB Extended Release (ER) 50mg capsule), once daily for 4 to 8 weeks.
RAB ER 50mg	Rabeprazole (RAB) Extended Release (ER) 50mg capsule concurrently with placebo (identical in appearance to the ESO 40mg capsule), once daily for 4 to 8 weeks.

Measured Values

	ESO 40mg	RAB ER 50mg
Participants Analyzed [Units: Participants]	537	528
Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4 [Units: Percentage of Participants]		
Yes	52.5	53.2
No	40	39.6
Missing	7.4	7.2

No statistical analysis provided for Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

► Serious Adverse Events

 Hide Serious Adverse Events

Time Frame	For each participant, from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug or up to resolution of adverse event or up to approximately 10 weeks.
Additional Description	Data are presented as number of participants with treatment emergent adverse events (serious and nonserious). The analysis was performed using Safety Analysis Set (SAS) defined as all subjects who received at least 1 dose of study drug and had a postbaseline safety assessment.

Reporting Groups

	Description
ESO 40mg	Esomeprazole (ESO) 40mg capsule concurrently with placebo (identical in appearance to the RAB Extended Release (ER) 50mg capsule), once daily for 4 to 8 weeks.
RAB ER 50mg	Rabeprazole (RAB) Extended Release (ER) 50mg capsule concurrently with placebo (identical in appearance to the ESO 40mg capsule), once daily for 4 to 8 weeks.

Serious Adverse Events

	ESO 40mg	RAB ER 50mg
Total, serious adverse events		
# participants affected / at risk	3/532 (0.56%)	3/526 (0.57%)
Gastrointestinal disorders		
Oesophageal stenosis † ¹		
# participants affected / at risk	1/532 (0.19%)	0/526 (0.00%)
Hepatobiliary disorders		
Cholecystitis † ¹		
# participants affected / at risk	1/532 (0.19%)	0/526 (0.00%)
Infections and infestations		
Pneumonia † ¹		
# participants affected / at risk	0/532 (0.00%)	1/526 (0.19%)
Pneumonia primary atypical † ¹		
# participants affected / at risk	0/532 (0.00%)	1/526 (0.19%)
Injury, poisoning and procedural complications		
Head injury † ¹		
# participants affected / at risk	0/532 (0.00%)	1/526 (0.19%)
Nervous system disorders		
Transient ischaemic attack † ¹		
# participants affected / at risk	1/532 (0.19%)	0/526 (0.00%)

† Events were collected by systematic assessment

¹ Term from vocabulary, MedDRA Version 11.1

▶ Other Adverse Events

▢ Hide Other Adverse Events

Time Frame	For each participant, from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug or up to resolution of adverse event or up to approximately 10 weeks.
Additional Description	Data are presented as number of participants with treatment emergent adverse events (serious and nonserious). The analysis was performed using Safety Analysis Set (SAS) defined as all subjects who received at least 1 dose of study drug and had a postbaseline safety assessment.

Frequency Threshold

Threshold above which other adverse events are reported	5
---	---

Reporting Groups

	Description
ESO 40mg	Esomeprazole (ESO) 40mg capsule concurrently with placebo (identical in appearance to the RAB Extended Release (ER) 50mg capsule), once daily for 4 to 8 weeks.
RAB ER 50mg	Rabeprazole (RAB) Extended Release (ER) 50mg capsule concurrently with placebo (identical in appearance to the ESO 40mg capsule), once daily for 4 to 8 weeks.

Other Adverse Events

	ESO 40mg	RAB ER 50mg

Total, other (not including serious) adverse events		
# participants affected / at risk	0/532 (0.00%)	0/526 (0.00%)

▶ Limitations and Caveats

☰ Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data

No text entered.

▶ More Information

☰ Hide More Information

Certain Agreements:

Principal Investigators are **NOT** employed by the organization sponsoring the study.

There is **NOT** an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Eisai Inc.
 Organization: Eisai Call Center
 phone: 888-422-4743

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. *Aliment Pharmacol Ther.* 2011 Jan;33(2):203-12. doi: 10.1111/j.1365-2036.2010.04516.x.

Responsible Party: Eisai Inc.
 ClinicalTrials.gov Identifier: NCT00658775 [History of Changes](#)
 Other Study ID Numbers: E3810-G000-302
 2007-006046-17 (EudraCT Number)
 Study First Received: April 9, 2008
 Results First Received: June 8, 2015
 Last Updated: November 19, 2015
 Health Authority: United States: Food and Drug Administration

▲ TO TOP

[For Patients and Families](#) | [For Researchers](#) | [For Study Record Managers](#)

[HOME](#) [RSS FEEDS](#) [SITE MAP](#) [TERMS AND CONDITIONS](#) [DISCLAIMER](#) [CONTACT NLM HELP DESK](#)